HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A4032 Emb01 (Anti-cMet & EGFR) Emb01 is a tetravalent, bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET) on tumor cells, preventing receptor activation and inducing receptor endocytosis, which effectively eliminates these targets on tumor cell surfaces. It demonstrates significant anti-tumor activity in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models, with the potential to treat EGFR antibody-resistant non-small cell lung cancer (NSCLC). MW: 237.9 KD. Mar 09 2025
A4033 RO7122290 (Anti-4-1BB & FAP) RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD. Mar 09 2025
A4034 Gen1042 (Anti-4-1BB & CD40) Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD. Mar 09 2025
A4035 Hpn536 (Anti-CD3e & Mesothelin & Serum Albumin) Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid tumors. MW: 52.92 KD. Mar 09 2025
A4036 Gen3009 (Anti-CD37) Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD. Mar 09 2025
A4037 Gen1044 (Anti-CD3 & TPBG) Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa. Mar 09 2025
A4038 Regn7075 (Anti-CD28 & EGFR) Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa. Mar 09 2025
A4039 Yh32367 (Anti-4-1BB & HER2) Yh32367 is a humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9). It exhibits potential immunostimulating and antineoplastic activities. M.W 200.52 kDa. Mar 09 2025
A4040 Emb-06 (Anti-BCMA & CD3) Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa. Mar 09 2025
A4041 Ngm707 (Anti-LILRB2 & LILRB4) Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa. Mar 09 2025
A4042 Ibi-334 (Anti-B7-H3 & EGFR) Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa. Mar 09 2025
A4043 Cova322 (Anti-IL-17 & TNF-Alpha) Cova322 is a bispecific FynomAb targeting TNF and IL-17A, created by fusing a small anti-IL-17A Fynomer to the anti-TNF antibody adalimumab. It shows potent inhibition of TNF and IL-17A in vitro and in vivo, offering potential benefits for inflammatory disease treatment. M.W 161.9 kDa. Mar 09 2025
A4044 Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa. Mar 09 2025
A4045 Odronextamab (Anti-CD20 & CD3) Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa. Mar 09 2025
A4046 Ozoralizumab (Anti-TNF-α) Ozoralizumab is a humanized trivalent, bispecific NANOBODY® targeting TNFα with two anti-TNFα domains and an anti-HSA domain. It demonstrates strong anti-arthritis efficacy in human TNF transgenic mice, effective both at arthritis onset and during secondary failure of anti-TNFα IgG therapy. M.W 38.44 kDa. Mar 09 2025
A4048 Afm24 (Anti-EGFR & Fc-gamma-RIIIA) Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa. Mar 09 2025
A4049 Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) HPN328 is a humanized, trispecific T-cell activating construct (TriTAC) targeting CD3 for T-cell engagement, HSA for half-life extension, and DLL3 on tumor cells. It induces potent T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and long-term anti-tumor immunity. M.W 53.06 kDa. Mar 09 2025
A4051 Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa Mar 09 2025
A4052 Faricimab (Anti-Angiopoietin 2 & VEGF-A) Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa Mar 09 2025
A4053 Reozalimab(Ibi318) (Anti-PD-1 & PD-L1) Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa Mar 09 2025